Absence of IDH1 and IDH2 mutations in the melanoma (or low occurrence in GBMs) indicates that these mutations are unlikely to be the major determinants promoting a loss of 5-hmC in melanomas, primary GBMs and prostate cancers. Here, IDH2 is linked to prostate cancer.